# Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine

> **NIH NIH R01** · STANFORD UNIVERSITY · 2020 · $842,000

## Abstract

7. Project Summary/Abstract
The overarching goal of this New Aim 4 is to test the hypothesis that SARS-CoV-2 (CoV-2) causes autoimmune
disease (AI) in a subset of infected patients. Our preliminary studies on 336 COVID-19 samples from 282 COVID19 patients (four COVID-19 cohorts in three geographically distinct regions) have identified autoantibodies and
clinical evidence of AI. To test the hypothesis that autoantibodies develop following CoV-2 infection, we will use
autoantigen arrays to identify proteins targeted by autoantibodies, some of which may cause pathogenic
inflammatory responses that could mediate lung, skin, and other tissue injury, dysregulated coagulation,
endothelial dysfunction, and vasculopathy. We will then test the hypothesis that autoantibodies develop through
different mechanisms including molecular mimicry and generation of receptor-blocking anti-cytokine antibodies
(ACA) in response to “cytokine storm”. We hypothesize that infection with CoV-2 induces 2 different outcomes:
(i) the desired outcome - protective responses that neutralize CoV-2; or (ii) pathogenic responses that lead to
symptomatic autoimmunity or autoinflammatory disease. Aim 4.1 will test the hypothesis that CoV-2 causes
development of autoantibodies and classifiable autoimmune diseases by leveraging our custom “COVID-19
Autoantigen Array” comprising common autoantigens from diseases that affect the lung, endothelium and skin.
Aim 4.2 will characterize serum antibodies specific for proteins from CoV-2 and other coronaviruses, and
correlate with autoantibodies in Aim 1, by using our “COVID-19 Viral Array” capable of simultaneously
quantitating antibodies against many different wild-type and mutant viral proteins and peptides. Viral responses
will be correlated with clinical outcomes including development of autoantibodies, and progression to clinical
autoimmunity. Aim 4.3 will test the hypothesis that CoV-2 causes autoimmunity through mechanisms including
cross-reactivity (molecular mimicry) and cytokine storm which generates receptor-blocking ACA. We will use a
variety of lab-based techniques to explore these mechanisms, including purification of antigen-specific IgG from
serum, co-immunoprecipitation, and cross-binding assays. Together, the proposed experiments will begin to
quantify the impact of CoV-2 on AI, identify which antigens and specific AI are associated with CoV-2, and
contribute to our mechanistic understanding of COVID-19 pathogenesis, setting the stage for large-scale
epidemiology studies to determine the extent of autoimmunity that results from CoV-2 infection, as well as longterm impacts on the health care system and economy.

## Key facts

- **NIH application ID:** 9975682
- **Project number:** 5R01AI125197-05
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** PAUL JOSEPH UTZ
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $842,000
- **Award type:** 5
- **Project period:** 2016-08-10 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9975682

## Citation

> US National Institutes of Health, RePORTER application 9975682, Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine (5R01AI125197-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9975682. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*